Table 3.
TO (n = 64) | TA (n = 32) | p | |
---|---|---|---|
Local lesion progression | 20 (31.3%) | 8 (25.0%) | |
Intrahepatic metastasis | 30 (46.9%) | 10 (31.3%) | |
Extrahepatic metastasis | 8 (12.5%) | 4 (12.4%) | |
death | 6 (9.3%) | 10 (31.3%) | 0.054 |
Data are presented as n (%),
TO, TACE only; TA, TACE combined with anlotinib; TACE, transarterial chemoembolization.